Outbreak of adverse reactions associated with contaminated heparin

New England Journal of Medicine

Volumn 359, Issue 25, 2008, Pages 2674-2684

  Blossom, David B ^a,b   Kallen, Alexander J ^a,b   Patel, Priti R ^a,b   Elward, Alexis ^c   Robinson, Luke ^f,g   Gao, Ganpan ^f,g   Langer, Robert ^f,g   Perkins, Kiran M ^a   Jaeger, Jennifer L ^a   Kurkjian, Katie M ^a   Jones, Marilyn ^d   Schillie, Sarah F ^a,b   Shehab, Nadine ^b   Ketterer, Daniel ^a   Venkataraman, Ganesh ^h   Kishimoto, Takashi Kei ^h   Shriver, Zachary ^h   McMahon, Ann W ⁱ   Austen, K Frank ^j   Kozlowski, Steven ⁱ   Srinivasan, Arjun ^b   Turabelidze, George ^e   Gould, Carolyn V ^b   Arduino, Matthew J ^b   Sasisekharan, Ram ^f,g   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

^d BJC HEALTHCARE   (United States)

^e MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^f Massachusetts Institute of Technology Cambridge   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h Momenta Pharmaceuticals Inc   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; HEPARIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD PRESSURE; CASE CONTROL STUDY; CHILL; CLINICAL FEATURE; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG EXPOSURE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG IDENTIFICATION; DYSPHAGIA; DYSPNEA; EDEMA; EPIDEMIC; EYELID EDEMA; FACE EDEMA; FEMALE; FLUSHING; HEMODIALYSIS; HUMAN; HYPOTENSION; LIP EDEMA; MAJOR CLINICAL STUDY; MALE; MOUTH EDEMA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; TACHYCARDIA; THROAT EDEMA; TONGUE EDEMA; UNCONSCIOUSNESS; URTICARIA; VOMITING; WHEEZING;

EID: 58049216683     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0806450     Document Type: Article

References (24)

1. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006;61:1432-40.
2. Bottio T, Pittarello G, Bonato R, Fagiolo U, Gerosa G. Life-threatening anaphylactic shock caused by porcine heparin intravenous infusion during mitral valve repair. J Thorac Cardiovasc Surg 2003;126:1194-5.
3. Acute allergic-type reactions among patients undergoing hemodialysis - multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008;57:124-5.
4. Recall - firm press release: Baxter issues urgent nationwide voluntary recall of heparin 1,000 units/ml 10 and 30ml multidose vials. Rockville, MD: Food and Drug Administration, 2008. (Accessed November 24, 2008, at http://www.fda.gov/oc/po/firmrecalls/baxter01_08.html.)
5. Recall - firm press release: Baxter to proceed with recall of remaining heparin sodium vial products. Rockville, MD: Food and Drug Administration, 2008. (Accessed November 24, 2008, at http://www.fda.gov/oc/po/firmrecalls/ baxter02_08.html.)
6. Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008;26:669-75.
7. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67.
8. Information on Dialysis Facility Compare. Baltimore: Centers for Medicare & Medicaid Services, 2008. (Accessed November 24, 2008, at http://www.medicare.gov/Dialysis/Include/DataSection/Questions/SearchCriteria. asp?version=default&browser=IE%7C6%7CWinXP&language=English& defaultstatus=0&pagelist=Home.)
9. Arduino MJ. CDC investigations of noninfectious outbreaks of adverse events in hemodialysis facilities, 1979-1999. Semin Dial 2000;13:86-91.
10. Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ. Haemodialysis-associated anaphylactic and anaphylactoid reactions. Allergy 2006;61:211-20.
11. Pegues DA, Beck-Sague CM, Woollen SW, et al. Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992;42:1232-7.
12. Zakkar M, Taylor K, Hornick PI. Immune system and inflammatory responses to cardiopulmonary bypass. In: Gravlee GP, Davis RF, Stammers AH, Ungerleider RM, eds. Cardiopulmonary bypass: principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2007:321-7.
13. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 2004;34:1916-8.
14. Walenga JM. Non-anticoagulant effects of unfractionated and low-molecular weight heparins. Clin Adv Hematol Oncol 2007;5:759-60.
15. Ludwig RJ, Alban S, Boehncke WH. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev Med Chem 2006;6:1009-23.
16. Maharaj C, Laffey JG. New strategies to control the inflammatory response in cardiac surgery. Curr Opin Anaesthesiol 2004;17:35-48.
17. Wan S, LeClerc JL, Antoine M, DeSmet JM, Yim AP, Vincent JL. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study. Ann Thorac Surg 1999;68:1230-5.
18. Pseudomonas bloodstream infections associated with a heparin/saline flush - Missouri, New York, Texas, and Michigan, 2004-2005. MMWR Morb Mortal Wkly Rep 2005;54:269-72.
19. Souza Dias MB, Habert AB, Borrasca V, et al. Salvage of long-term central venous catheters during an outbreak of Pseudomonas putida and Stenotrophomonas maltophilia infections associated with contaminated heparin catheter-lock solution. Infect Control Hosp Epidemiol 2008;29:125-30.
20. Vonberg RP, Gastmeier P. Hospital-acquired infections related to contaminated substances. J Hosp Infect 2007;65:15-23.
21. Schwartz LB. Heparin comes clean. N Engl J Med 2008;358:2505-9.
22. Bishu K, Gricz KM, Chewaka S, Agarwal R. Appropriateness of antihypertensive drug therapy in hemodialysis patients. Clin J Am Soc Nephrol 2006;1:820-4.
23. Leypoldt JK, Cheung AK, Delmez JA, et al. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int 2002;61:266-75.
24. Information on adverse event reports and heparin. Rockville, MD: Food and Drug Administration, 2008. (Accessed November 24, 2008, at http://www.fda.gov/ cder/drug/infopage/heparin/adverse_events.htm.)